Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: Jefferson Research
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Abbott Laboratories Presents Promising Phase 2b Interferon-free Hepatitis C Results at 2012 Liver Meeting


Saturday, 10 Nov 2012 09:00am EST 

Abbott Laboratories announced results from its phase 2b clinical trial, 'Aviator', demonstrated high sustained viral response rates at 12 weeks post-treatment (SVR12) in all 8- and 12-week arms, with combinations of direct acting antivirals (DAAs) given with and without ribavirin (RBV). Results will be presented at the President's Press Conference and the latebreaking clinical trials session at the Liver Meeting, the Annual Meeting of the American Association for the Study of Liver Disease (AASLD) in Boston. Based on promising results from Aviator, Abbott has selected triple-DAA regimens, with and without ribavirin, to move forward into phase 3 clinical trials. Topline intent-to-treat results for the 12-week, triple-DAA regimen with ribavirin are as follows: SVR12 in treatment-naïve genotype 1 (GT1) patients was 97.5% (77 of 79), and 93.3% (42 of 45) in GT1 null responder patients ; GT1a patients, SVR12 was achieved in 96% (52 of 54) of treatment naïve patients and 89% (25 of 28) of null responder patients; and In GT1b patients, SVR12 was achieved in 100% of treatment naïve (25 of 25) and null responder patients (17 of 17). 

Company Quote

41.26
0.24 +0.59%
11 Jul 2014